北京生物医学工程

蛋白激酶CK2天然产物类抑制剂的定量构效关系研究

Quantitative structure-activity relationship studies on natural product inhibitors of protein kinase CK2

作者：张雪文张娜李春华孙国辉赵丽娇钟儒刚

单位：北京工业大学环境与生命学部（北京 100124）<br />通信作者：张娜。E-mai：nanatonglei@bjut.edu.cn

关键词：蛋白激酶CK2；天然产物类抑制剂；定量结构-活性关系；遗传算法；多元线性回归

分类号：R318.04

出版年·卷·期（页码）：2023·42·1（81-87）

摘要：

目的构建CK2天然产物类抑制剂的定量构效关系(quantitative structure-activity relationship, QSAR)模型，揭示影响该类抑制剂活性的结构因素，为新型CK2抑制剂的开发提供理论基础和实验依据。方法基于文献报道的115个多骨架CK2天然产物类抑制剂，采用遗传算法（genetic algorithm，GA）联合多元线性回归（multiple linear regression，MLR）方法，建立了基于优选的Dragon描述符的QSAR模型，以留一法交叉验证系数Q2LOO以及相关系数R2作为模型内部验证的评价指标；通过Q2ext和 R2ext评估模型的外部预测能力。结果最优2D-QSAR模型由8个描述符组成，基于训练集内部验证的统计学参数为Q2Loo=0.7914、R2=0.8220；基于测试集外部验证的统计学参数为Q2ext=0.7921、R2ext=0.7998，表明该模型具有较高的可靠性和预测能力。结论该模型表明，影响CK2天然产物类抑制剂活性的分子描述符包括IVDE、CATS2D_08_DA、nArX、IC1、Chi_D/Dt、SdssC、F08[C-O]以及C-006，可为新型CK2抗癌抑制剂的发现提供实验指导。

Objective To build the quantitative structure-activityy relationship model of CK2 natural products inhibitors ，and to elucidate the underlying structural factors influencing their inhibitory activity. This study will provide the theoretical basis and experimental guidance for the development of new protein kinase CK2 inhibitors. Methods Based on 115 CK2 natural product inhibitors with diverse chemical scaffolds reported in the published literature, genetic algorithm (GA) and multiple linear regression (MLR) methods, combined with preferred molecular descriptors calculated by Dragon, were employed to build the 2D-QSAR model.. The leave-one-out cross-validation coefficient Q2LOO and the correlation coefficient R2 were used as the evaluation indicators for the internal verification of the model, and the external predictive ability of the model was evaluated through Q2ext and R2ext. Results The best model composed of 8 molecular descriptors possessed Q2Loo=0.7914、R2=0.8220 with leave one out cross-validation of training set and Q2ext=0.7921、R2ext=0.7998 of external validation, which indicated that the model had the robust reliability and high predictability. Conclusions The results clearly indicate that the anti-CK2 activity of natural product inhibitors is mainly related to the descriptors IVDE CATS2D_08_DA, nArX, IC1, Chi_D/Dt, SdssC, F08[CO] and C-006. This study can provide experimental guidance for the discovery of novel CK2 anti-cancer inhibitors

参考文献：

[1] Husain K, Williamson TT, Nelson N, etal. Protein kinase 2 (CK2): a potential regulator of immune cell development and function in cancer[J]. Immunological Medicine, 2020,9:1-16..
[2] Piazza F, Manni S, Ruzzene M, et al. Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways[J]. Leukemia,2012, 26(6):1174-1179.
[3] Bouhaddou M, Memon D,Meye B, et al. The global phosphorylation landscapeof SARS-CoV-2 infection [J]. Cell，2020, 182:685-712.
[4] Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy[J]. Nature Reviews Cancer,2017,17(2):93-115.
[5] Cozza G. The Development of CK2 Inhibitors: From traditional pharmacology to in silico rational drug design[J]. Journal of Biological Chemistry, 2017,10(1):700-703.
[6] Qiao Y, Chen T, Yang H,et al. Small molecule modulators targeting protein kinase CK1 and CK2[J]. European Journal of Medicinal Chemistry, 2019,181:111581.
[7] Raaf J, Klopffleisch K, Issinger O, et al. The catalytic subunit of human protein kinase CK2 structurally deviates from its maize homologue in complex with the nucleotide competitive inhibitor emodin[J]. Journal of Molecular Biology, 2008, 377(1): 1-8.
[8] Chilin A, Battistutta R, Bortolato A,et al.Coumarin as attractive casein kinase2 (CK2) inhibitor scaffold: An integrate approach to elucidate the putative binding motif and explain structure-activity relationships[J]. Journal of Medicinal Chemistry,2008, 51(4): 752-759.
[9] LollI G, Cozza G, Mazzorana M, et al. Inhibition of protein kinase CK2 by flavonoids and tyrphostins. A structural insight[J]. Biochemistry, 2012, 51(31): 6097-6107.
[10] Golub AG, Bdzhola VG, Ostrynska OV, et al. Discovery and characterization ofsynthetic 4'-hydroxyflavones New CK2 inhibitors from flavone family[J].Bioorganic & Medicinal Chemistry, 2013, 21(21): 6681-6689.
[11] 李春梅, 刘新光, 林小聪,等. 七种黄酮类化合物对重组人蛋白激酶CK2全酶抑制作用的结构效应关系[J]. 中南大学学报(医学版), 2009, 34(1):20-26.
Li CM,Liu XG,LinXC,et al. Structure-activity relationship of 7 flavonoids on recombinant human protein kinase CK2 holoenzyme [J].Journal of Central South University (Medical Edition),2009, 34(1):20-26.
[12] Sekiguchi Y, Nakaniwa T, Kinoshita T, et al. Structural insight into human CK2αin complex with the potent inhibitor ellagic acid[J]. Bioorganic & Medicinal Chemistry Letters, 2009, 19(11): 2920-2923.
[13] Qi XQ, Zhang N, Zhao LJ, et al. Structure-based identification of novel CK2 inhibitors with a linear 2-propenone scaffold as anti-cancer agents[J]. Biochemical and Biophysical Research Communications,2019, 512(2):208-212.
[14] Pourbasheer E, Aalizadeh R , Ganjali MR . QSAR study of CK2 inhibitors by GA-MLR and GA-SVM methods[J]. Arabian Journal of Chemistry, 2015, 9(8):355-370.
[15] Cui W, Aouidatea, Wang S, et al. Discovering anti-cancer drugs via computational methods[J]. Front Pharmacol,2020, 11:733.
[16] Zhang N, Zhong RG. Docking and 3D-QSAR studies of 7-hydroxycoumarin derivatives as CK2 inhibitors[J]. European Journal of Medicinal Chemistry, 2010, 45(1):292-297.
[17] Zhang N, Chen WJ, Zhou Y, et al. Rational design of Coumarin derivatives as CK2 inhibitors by improving the interaction with the hinge region[J]. Molecular Informatics, 2016, 35(1):15-8.
[18] Ul-Haq Z, Ashraf S, Bkhaitan MM. Molecular dynamics simulations reveal structural insights into inhibitor binding modes and mechanism of casein kinase II inhibitors[J]. Journal Of Biomolecular Structure & Dynamics, 2019,37(5):1120-1135.?
[19] Zhang N, Chen W J,Zhou Y, et al. 3D-QSAR study of flavones as CK2 inhibitors by a combined computational modeling[J]. Basic & Clinical Pharmacology & Toxicology, 2016, 119:10-11.
[20] Battistutta R, Lolli G. Inhibitory properties of ATP-competitive coumestrol and boldine are correlated to different modulations of CK2 flexibility[J]. Journal of Natural Products, 2019,82(4):1014-1018.
[21] Cozza G, Zonta F, Vedove A, et al. Biochemical and cellular mechanism of protein kinase CK2 inhibition by deceptive curcumin[J]. FEBS J ournal, 2020, 287(9):1850-1864.
[22] Gramatica P, Chirico N, Papa E, et al. QSARINS: A new software for the development, analysis, and validation of QSAR MLR models [J]. Journal of Computationa,2013, 34(24):2121-2132.
[23] Gramatica P, Cassani S, Chirico N. QSARINS-Chem: Insubria datasets and new QSAR/QSPR models for environmental pollutants in QSARINS [J]. Journal of Computational Chemistry, 2014, 35(13): 1036-1044.
[24] Wu W, Zhang C, Lin W, et al. Quantitative structure-property relationship (QSPR) modeling of drug-loaded polymeric micelles via genetic function approximation[J].Plos One,2015,10(3):e0119575.
[25] 覃礼堂,刘树深,肖乾芬,等. QSAR模型内部和外部验证方法综述[J]. 环境化学, 2013, 32(7):1205-1211.
Qin LT, Liu SS, Xiao QF, etal. Internal and external validations of QSAR model: Review [J]. Environmental Chemistry, 2013, 32(7):1205-1211.
[26] Fan TJ, Sun GH, Zhao LJ, et al. QSAR and classification study on prediction of acute oral toxicity of N-nitroso compounds[J]. International Journal of Molecular Sciences, 2018, 19( 10) : 3015－3036．
[27] Golbraikha, Tropsha A. Beware of q2![J]. Journal of Molecular Graphics & Modelling,2002,20(4): 269-276．
[28] Roy K, Mitra I, Kar S, et al. Comparative studies on some metrics for external validation of QSPR models[J]. Journal of Chemical Information and Modeling, 2012, 52( 2)：396-408.
[29] Todeschini R, ConsonniV. Handbook of molecular descriptors[J]. Weinheim, Germany :Wiley-VCH, 2008.
[30] Sarno S, Papinutto E, Franchin C, et al. ATP site-directed inhibitors of protein kinase CK2: an update [J]. Current Topics in Medicinal Chemistry, 2011, 11(11): 1340-1351.
[31] Pierre F, Chua PC, O'Brien SE,et al. Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer[J]. Journal Of Medicinal Chemistry, 2011,54(2):635-654.

服务与反馈：

【文章下载】【加入收藏】

提示：您还未登录，请登录！点此登录